Byczy
Pfizer's stock rises 2.43% to $25.25 amid positive analyst outlook.
Ten briefing nie jest jeszcze dostępny w tym języku — wyświetlana jest wersja angielska.
Pfizer's stock price increased by 2.43% to $25.25, following positive analyst assessments. RBC Capital upgraded Pfizer's rating to 'Sector Perform' with a $25.00 price target, citing improved valuation and upcoming catalysts. Additionally, the Swiss National Bank increased its stake in Pfizer by 7.1%, now holding approximately 16.7 million shares valued at $468.5 million.
Kluczowe punkty
- RBC Capital upgrades Pfizer's rating to 'Sector Perform' with a $25.00 price target, citing improved valuation and upcoming catalysts.
- Swiss National Bank increases its stake in Pfizer by 7.1%, now holding approximately 16.7 million shares valued at $468.5 million.
- Pfizer's stock price rises 2.43% to $25.25 amid positive analyst outlook.
Źródła
Wygenerowane przez AI na podstawie publicznych źródeł wiadomości. To nie jest porada finansowa.
